23-04-2020 дата публикации
Номер: US20200121804A1
The invention provides compositions comprising a single protein having one or more molecules of a pharmaceutical agent tightly bound therein. The compositions are useful to decrease the toxicity and/or to widen the therapeutic window of the pharmaceutical agent. The invention also provides methods for preparing such a composition. 1. A composition comprising , a single protein having one or more molecules of a pharmaceutical agent tightly bound therein.2. The composition of claim 1 , wherein the single protein is an albumin claim 1 , a globulin claim 1 , or a fibrinogen.3. The composition of claim 1 , wherein the single protein is an albumin.4. The composition of claim 1 , wherein the single protein is IgG.5. The composition of claim 1 , wherein the pharmaceutical agent comprises an amino group.6. The composition of claim 1 , wherein the pharmaceutical agent comprises a carboxyl group.7. The composition of claim 1 , wherein the pharmaceutical agent is an anti-cancer compound.8. The composition of claim 1 , wherein the pharmaceutical agent is doxorubicin claim 1 , mitoxantrone claim 1 , daunorubicin claim 1 , epirubicin claim 1 , idarubicin claim 1 , vincristine claim 1 , vinorelbine claim 1 , vinblastine claim 1 , topotecan claim 1 , irinotecan claim 1 , actinomycin D claim 1 , idarubicin claim 1 , methotrexate claim 1 , pemetrexed claim 1 , raltitrexed claim 1 , SN-38 claim 1 , ixabepilone claim 1 , eribulin claim 1 , vindesine claim 1 , camptothecin claim 1 , taxol claim 1 , docetaxel claim 1 , bendamustine claim 1 , nelarabine claim 1 , pirarubicin claim 1 , clofarabine claim 1 , valrubicin claim 1 , chlorambucil claim 1 , or melphalan.9. The composition of claim 1 , wherein the pharmaceutical agent is doxorubicin.10. The composition of claim 1 , wherein the pharmaceutical agent is an antibiotic.11. The composition of claim 1 , wherein the maximum tolerated dose of the pharmaceutical agent in the composition is at least 10% greater than the maximum tolerated dose ...
Подробнее